Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
American Heart Journal|June 5, 2017
Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trialMaya Guglin, Pamela Munster, Angelina Fink, et al.
Oncotarget|June 8, 2018
Thyroid function in the etiology of fatigue in breast cancerNagi B Kumar, Angelina Fink, Silvina Levis, et al.
Journal of the American College of Cardiology|June 8, 2019
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast CancerMaya Guglin, Jeffrey Krischer, Roy Tamura, et al.
Geburtshilfe Und Frauenheilkunde|June 13, 2025
Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?Stefan Lukac, Kerstin Pfister, Henning Schäffler, et al.
Geburtshilfe Und Frauenheilkunde|June 13, 2025
Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?Stefan Lukac, Kerstin Pfister, Henning Schäffler, et al.
Archives of Gynecology and Obstetrics|February 19, 2026
Age-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trialsStefan Lukac, Davut Dayan, Wolfgang Janni, et al.
Oncology Research and Treatment|February 25, 2025
Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?Kerstin Pfister, Henning Schäffler, Sophia Huesmann, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
American Journal of Clinical Oncology|October 5, 2019
Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative StudyFrancis A Asamoah, Joel Yarney, Shivanshu Awasthi, et al.
Pageof 2